Renal Cancer

  • C. W. Ryan
  • N. J. Vogelzang


In 2001, it was estimated that over 30,000 new cases of renal cell carcinoma (RCC) occurred in the United States, and that 12,100 people died of the disease [1]. Of all patients diagnosed with RCC, 50% survive beyond 10 years and over 14,000 longterm survivors of the disease are added to the United States population each year. The incidence of RCC has been slowly increasing over the past 25 years, due in part to increased detection through improved imaging techniques, but likely influenced by other factors [2]. The major risk factors beyond male gender and age over the age of 60 include cigarette smoking, obesity, hypertension, and a variety of occupational exposures [3, 4]. Patients with chronic renal failure on or off dialysis have a greater than 30-fold excess risk of RCC [5].


Renal Cell Carcinoma Clin Oncol Metastatic Renal Cell Carcinoma Radical Nephrectomy Advanced Renal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics 2001. CA Cancer J Clin 51:15–36PubMedCrossRefGoogle Scholar
  2. 2.
    Chow WH, Devesa SS, Warren JL et al (1999) Rising incidence of renal cell cancer in the United States. JAMA 281: 1628–1631PubMedCrossRefGoogle Scholar
  3. 3.
    Coughlin SS, Neaton JD, Randall B, Sengupta A (1997) Predictors of mortality from kidney cancer in 332,547 men screened for the multiple risk factor intervention trial. Cancer 79:2171–2177PubMedCrossRefGoogle Scholar
  4. 4.
    Mandel JS, McLaughlin JK, Schlehofer B et al (1995) International renal-cell cancer study. IV. Occupation. Int J Cancer 61:601–605PubMedCrossRefGoogle Scholar
  5. 5.
    Ishikawa I, Kovacs G (1993) High incidence of papillary renal cell tumours in patients on chronic haemodialysis. Histopathology 22:135–139PubMedCrossRefGoogle Scholar
  6. 6.
    LaForgia S, Lasota J, Latif F, Boghosian-Sell L, Kastury K, Ohta M, Druck T, Atchison L, Cannizzaro LA, Barnea G (1993) Detailed genetic and physical map of the 3p chromosome region surrounding the familial renal cell carcinoma chromosome translocation, t(3;8)(pl4.2;q24.1). Cancer Res 53:3118–3124PubMedGoogle Scholar
  7. 7.
    Linehan WM, Lerman MI, Zbar B (1995) Identification of the von Hippel-Lindau gene: its role in renal carcinoma. JAMA 273:564–570PubMedCrossRefGoogle Scholar
  8. 8.
    Zbar B, Tory K, Merino M, Schmidt L, Glenn G, Choyke P, Walther MM, Lermann M, Linehan WM (1994) Hereditary papillary renal cell carcinoma. J Urol 151:561–566PubMedGoogle Scholar
  9. 9.
    American Joint Committee on Cancer (1997) Kidney. In: Fleming ID, Cooper JS, Henson DE et al (eds) Manual for staging of cancer, 5th edn. Lippincott, Philadelphia, pp 231–234Google Scholar
  10. 10.
    Guinan PD, Vogelzang NJ, Fremgen AM, Chmiel JS, Sylvester JL, Sener SF, Imperato JP (1995) Renal cell carcinoma: tumor size, stage and survival. J Urol 153:901–903PubMedCrossRefGoogle Scholar
  11. 11.
    Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19:1649–1699PubMedGoogle Scholar
  12. 12.
    Kiely JM (1966) Hypernephroma–the internist’s tumor. Med Clin North Am 50:1067–1083PubMedGoogle Scholar
  13. 13.
    Ritchie AWS, Chisholm GD (1983) The natural history of renal carcinoma. Semin Oncol 10:390–400PubMedGoogle Scholar
  14. 14.
    Johnson CD, Dunnick NR, Cohan RH, Illescas FI (1987) Renal adenocarcinoma: CT staging of 100 tumors. Am J Roentgenol 148:59–63Google Scholar
  15. 15.
    Horan JJ, Robertson CN, Choyke PL, Frank JA, Miller DL, Pass HI, Linehan WM (1989) The detection of renal carcinoma extension into the renal vein and inferior vena cava: a prospective comparison of venacavography and magnetic resonance imaging. J Urol 142:943–948PubMedGoogle Scholar
  16. 16.
    Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101:297–301PubMedGoogle Scholar
  17. 17.
    Guiliani L, Giberti L, Martorana G, Rovida S (1990) Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143:468–474Google Scholar
  18. 18.
    Dunn MD, Portis AJ, Shalhav AL, Elbahnasy AM, Heidorn C, McDougall EM, dayman RV (2000) Laparoscopic versus open radical nephrectomy: a 9-year experience. J Urol 164:1153–1159PubMedCrossRefGoogle Scholar
  19. 19.
    Novick AC (1995) Current surgical approaches, nephronsparing surgery, and the role of surgery in the integrated immunologic approach to renal-cell carcinoma. Semin Oncol 22:29–33PubMedGoogle Scholar
  20. 20.
    Belldegrun A, Tsui KH, de Kernion JB et al (1999) Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol 17:2868–2875PubMedGoogle Scholar
  21. 21.
    Kjaer M, Frederiksen PL, Engelholm SA (1987) Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 13:665–672PubMedCrossRefGoogle Scholar
  22. 22.
    Motzer RJ, Bander NH, Nanus DM (1996) Renal cell carcinoma. N Engl J Med 355:865–875CrossRefGoogle Scholar
  23. 23.
    Chapman AE, Goldstein LJ (1995) Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma. Semin Oncol 22:17–28PubMedGoogle Scholar
  24. 24.
    Motzer RJ, Vogelzang NJ (1997) Chemotherapy for renal cell carcinoma. In: Raghavan D, Scher HI, Leibel SA, Lange PH (eds) Principles and practice of genitourinary oncology, vol 85. Lippincott-Raven, Philadelphia, pp 885–896Google Scholar
  25. 25.
    Rini BI, Vogelzang NJ, Dumas MC, Wade JL III, Taber DA, Stadler WM (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18:2419–2426PubMedGoogle Scholar
  26. 26.
    Quesada JR, Swanson DA, Trindade A, Gutterman JU (1983) Renal cell carcinoma: anti-tumor effects of leukocyte interferon. Cancer Res 43:940–947PubMedGoogle Scholar
  27. 27.
    Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368–1375PubMedGoogle Scholar
  28. 28.
    Pyrhonen S, Salminen E, Ruutu M et al (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17:2859–2867PubMedGoogle Scholar
  29. 29.
    Ritchie A, Griffiths G, Parmar M, for the Medical Research Council Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353:14–17CrossRefGoogle Scholar
  30. 30.
    Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007–1008PubMedCrossRefGoogle Scholar
  31. 31.
    Rosenberg SA, Lotze MT, Muul JM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Rubin JT (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897PubMedCrossRefGoogle Scholar
  32. 32.
    Rosenberg SA, Yang JC, Topalian SC, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271:907–913PubMedCrossRefGoogle Scholar
  33. 33.
    Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688–696PubMedGoogle Scholar
  34. 34.
    Fisher RI, Rosenberg SA, Fyfe G (2000) Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6[Suppl 1]: S55–S57PubMedGoogle Scholar
  35. 35.
    Siegel JP, Puri RK (1991) Interleukin-2 toxicity. J Clin Oncol 9:694–704PubMedGoogle Scholar
  36. 36.
    Yang JC, Topalian SL, Parkinson D, Schwartzentruber DJ, Weber JS, Ettinghausen SE et al (1994) Randomized comparison of high-dose and low-dose intravenous interleukin-2 for therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 12:1572–1576PubMedGoogle Scholar
  37. 37.
    Stadler WM, Vogelzang NJ (1995) Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Semin Oncol 22:67–73PubMedGoogle Scholar
  38. 38.
    Yang JC, Rosenberg SA (1997) An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 3 [Suppl 1]:S68–S69Google Scholar
  39. 39.
    Figlin RA, Pierce WC, Belldegrun A (1993) Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma. Semin Oncol 20[Suppl 9]:11–15PubMedGoogle Scholar
  40. 40.
    Atkins MB, Sparano J, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR (1993) Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J Clin Oncol 11:661–670PubMedGoogle Scholar
  41. 41.
    Negrier S, Escudier B, Lasset C, Douillard J-Y, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Turz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338:1272–1278PubMedCrossRefGoogle Scholar
  42. 42.
    McDermott D, Flaherty L, Clark J, Weiss G, Logan T, Gordon M, Sosman J, Ernstoff M, Urba W, Margolin K, Atkins M (2001) A randomized phase III trial of high-dose interleukin-2 (HD IL2) versus su (SC) IL2/interferon (IFN) in patients with metastatic renal cell carcinoma (RCC) (abstract). Proc Am Soc Clin Oncol 20:685AGoogle Scholar
  43. 43.
    Hoffman AD, Engelstein D, Bogenrieder T et al (1996) Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res 2: 1077–1082PubMedGoogle Scholar
  44. 44.
    Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972–2980PubMedGoogle Scholar
  45. 45.
    Negrier S, Caty A, Lesimple T, Douillard JY, Escudier B, Rossi JF, Viens P, Gomez F (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluinoma. J Clin Oncol 18:4009–4015PubMedGoogle Scholar
  46. 46.
    Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, et al (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer 77:2560–2566PubMedCrossRefGoogle Scholar
  47. 47.
    Trump DL, Elson P, Propert K, Pontes J, Crawford E, Wilding P, et al (1996) Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon in resected, high-risk renal cell carcinoma (abstract). Proc Am Soc Clin Oncol 15:648AGoogle Scholar
  48. 48.
    Sawczuk IS, Graham SD, Miesowicz F (1997) Randomized, controlled trial of adjuvant therapy with ex vivo activated T cells (ALT) in Tl-3a,b,c or T4 N+M0 renal cell carcinoma (abstract). Proc Am Soc Clin Oncol 16:326AGoogle Scholar
  49. 49.
    Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubini E (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19:425–431PubMedGoogle Scholar
  50. 50.
    Levy DA, Swanson DA, Slaton JW, Ellerhorst J, Dinney CPN (1998) Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol 159:1168–1173PubMedCrossRefGoogle Scholar
  51. 51.
    Fleischmann JD, Kim B (1991) Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 145:938–941PubMedGoogle Scholar
  52. 52.
    Sella A, Swanson DA, Ro JY, Putman JB Jr, Amato RJ, Markowtiz AB, Logothetis CJ (1993) Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol 149:19–22PubMedGoogle Scholar
  53. 53.
    Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alpha-2b compared with interferon alpha 2-b alone for metastatic renalcell cancer. N Engl J Med 345:1655–1659PubMedCrossRefGoogle Scholar
  54. 54.
    Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheralblood stem-cell transplantation. N Engl J Med 343:802–803CrossRefGoogle Scholar
  55. 55.
    Rini BI, Zimmerman TM, Gajewski TF, Stadler WM, Vogelzang NJ (2001) Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol 165:1208–1209PubMedCrossRefGoogle Scholar
  56. 56.
    Gitlitz BJ, Belldegrun AS, Figlin RA (2001) Vaccine and gene therapy of renal cell carcinoma. Semin Urol Oncol 19: 141–147PubMedGoogle Scholar
  57. 57.
    Wittig B, Marten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kruopis S, Albers A, Loffel J, Neubauer A, Albers P, Muller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IG (2001) Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther 12:267–278PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • C. W. Ryan
  • N. J. Vogelzang

There are no affiliations available

Personalised recommendations